Status:
UNKNOWN
Secondary Prognostic Index in RefrActory Lymphoma
Lead Sponsor:
Weprom
Conditions:
Diffuse Large B Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
60% of patients with diffuse large B cell lymphoma are healed after first-line treatment which whatever the age. For the remaining 40% of patients (relapses and primary refractories): * 38% of patien...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- died of diffuse large B cell lymphoma
- Refractory or relapsing after 2 treatment lines for young patients (RCHOP then recovery with platinum salts and autograft) and one line for elderly patients (RCHOP)
Exclusion
- patients with HIV infection
- solid tumor treated less than 5 years ago with the exception of skin carcinoma or carcinoma in situ of the uterine cervix treated locally
- inclusion in a therapeutic trial
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04804865
Start Date
January 1 2020
End Date
June 1 2022
Last Update
March 23 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Victor Hugo / Centre Jean Bernard
Le Mans, France, 72000
2
Centre d'Oncologie de Gentilly
Nancy, France, 54000